NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/30/2026
Back to search
Official data from USPTO
DENDRITIC CELL THERAPY RGCC
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
06/30/2026
Classification
Registered
Trademark type
Combined
Nice classes
5, 42, 44
Filing date
09/11/2025
Registration date
06/30/2026
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/30/2026
Last transaction
06/30/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
25
Owner location
CH
Examiner
WLODARCZYK, CAROLYN A
Law office
L90
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the stylized wording "DENDRITIC CELL THERAPY RGCC" with the wording "DENDRITIC CELL" appearing on one line with "THERAPY RGCC" underneath. To the left of the wording appears a stylized cell design inside a circle.
Holders and representatives
Holders
R.G.C.C. Holdings AG
Representatives
James R Menker Holley & Menker, PA
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products for the treatment of cancer; Pharmaceutical products for immune response modification; Medical preparations for the treatment of cancer; Medical preparations for immune response modification; Pharmaceutical products for modulating immune response; Medical preparations for modulating immune response; Pharmaceutical products for immunotherapyT cell therapycell therapy; Medical preparations for immunotherapyT cell therapycell therapy
Class 42
Scientific research for medical purposes in the area of cancerous diseasescancer treatmentimmune responseimmunotherapyT cell therapycell therapy
Class 44
Medical diagnosis servicesmedical analysis services for the diagnosis of cancer
Publications
History of USPTO decisions and trademark events.
22 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/30/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/12/2026
PUBO
PUBLISHED FOR OPPOSITION
05/12/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/06/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/13/2026
XAEC
EXAMINER'S AMENDMENT ENTERED
04/13/2026
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/13/2026
GNEA
EXAMINERS AMENDMENT E-MAILED
04/13/2026
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/13/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/11/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/11/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/11/2026
RFNT
REFUSAL PROCESSED BY IB
03/26/2026
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/09/2026
RFRR
REFUSAL PROCESSED BY MPU
03/09/2026
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/09/2026
CNRT
NON-FINAL ACTION WRITTEN
02/08/2026
DOCK
ASSIGNED TO EXAMINER
02/07/2026
MAFR
APPLICATION FILING RECEIPT MAILED
02/06/2026
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/06/2026
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/29/2026
Continuous trademark protection
Get notified about every new filing that threatens DENDRITIC CELL THERAPY RGCC or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.